A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Clinical trial NCT04911998 · COMPLETED

Trial details

NCT number: NCT04911998
Sponsor: Pierre Fabre Medicament
Status: COMPLETED
Study type: OBSERVATIONAL

Melanoma (Skin)Metastatic Melanoma BRAF V600 Mutation

Start date: 2021-02-02
Primary completion: 2024-03-29
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.